TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
Animals
Antineoplastic Agents
/ pharmacology
Carcinoma, Squamous Cell
/ drug therapy
Cell Line, Tumor
/ drug effects
Epithelial Cells
/ drug effects
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ drug therapy
Mice
Molecular Targeted Therapy
Protein Kinase Inhibitors
/ pharmacology
Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
05
06
2020
revised:
21
11
2020
accepted:
20
01
2021
pubmed:
27
1
2021
medline:
19
2
2022
entrez:
26
1
2021
Statut:
ppublish
Résumé
Lung squamous cell carcinoma (LSCC) is the second most prevalent type of lung cancer. Despite extensive genomic characterization, no targeted therapies are approved for the treatment of LSCC. Distal amplification of the 3q chromosome is the most frequent genomic alteration in LSCC, and there is an urgent need to identify efficacious druggable targets within this amplicon. We identify the protein kinase TNIK as a therapeutic target in LSCC.
Identifiants
pubmed: 33495197
pii: 2159-8290.CD-20-0797
doi: 10.1158/2159-8290.CD-20-0797
pmc: PMC8178189
mid: NIHMS1668020
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
TNIK protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1411-1423Subventions
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM102262
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011691
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Nat Commun. 2016 Aug 26;7:12586
pubmed: 27562646
Clin Cancer Res. 2015 May 15;21(10):2236-43
pubmed: 25979930
Oncogene. 2016 Feb 4;35(5):537-48
pubmed: 25893302
Cancer Cell. 2014 Feb 10;25(2):139-51
pubmed: 24525231
Clin Cancer Res. 2012 Jun 1;18(11):3002-7
pubmed: 22461458
PLoS Biol. 2019 Mar 21;17(3):e2006540
pubmed: 30897078
Neoplasia. 2019 Apr;21(4):389-400
pubmed: 30901730
J Biol Chem. 2018 Dec 28;293(52):20014-20028
pubmed: 30442712
FEBS Lett. 2014 Aug 19;588(16):2743-52
pubmed: 24726726
J Biol Chem. 1993 Aug 15;268(23):17309-16
pubmed: 8349614
Oncogene. 2006 Sep 28;25(44):5960-8
pubmed: 16652148
Nat Rev Cancer. 2005 Jul;5(7):505-15
pubmed: 16069815
Genes Dev. 2020 Apr 1;34(7-8):511-525
pubmed: 32115406
Am Soc Clin Oncol Educ Book. 2015;:123-8
pubmed: 25993150
Neoplasia. 2011 Jul;13(7):643-52
pubmed: 21750658
J Proteome Res. 2013 Jun 7;12(6):2414-21
pubmed: 23312004
Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99
pubmed: 12154370
Cancer Res. 2010 Jun 15;70(12):5024-33
pubmed: 20530691
Ann Oncol. 2017 Oct 1;28(10):2595-2605
pubmed: 28945830
J Clin Invest. 2012 Feb;122(2):624-38
pubmed: 22232214
EMBO J. 2009 Nov 4;28(21):3329-40
pubmed: 19816403
J Proteomics. 2013 Oct 8;91:286-96
pubmed: 23911959
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Struct Mol Biol. 2020 Jan;27(1):92-104
pubmed: 31925410
Dev Cell. 2012 Apr 17;22(4):703-5
pubmed: 22516197
Mol Cancer Ther. 2014 Nov;13(11):2738-50
pubmed: 25193510
J Proteome Res. 2013 Jan 4;12(1):260-71
pubmed: 23186163
Methods Enzymol. 2014;548:117-46
pubmed: 25399644
Nat Cell Biol. 2007 Oct;9(10):1199-207
pubmed: 17891137
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
J Cell Sci. 2015 Mar 15;128(6):1253
pubmed: 25774052
Cancer Discov. 2013 Sep;3(9):1044-57
pubmed: 23764425
Adv Biol Regul. 2016 Jan;60:47-63
pubmed: 26754874